For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Epimmune Inc.

USPTO Granted Patents = 17

% Expired Patents = 17.6

EPO Patents = 11

Forward Citations = 439

Loading Chart...

Loading Chart...

30 inventors (with patents filed for the assignee):

Alessandro D Sette (13 out of 42 patents)

John Sidney (9 out of 17 patents)

Scott Southwood (9 out of 12 patents)

4. Robert W Chesnut (7 out of 15 patents)

5. Esteban Celis (7 out of 19 patents)

6. Howard M Grey (7 out of 16 patents)

7. Brian D Livingston (5 out of 11 patents)

8. Ralph T Kubo (4 out of 7 patents)

9. Mark Joseph Newman (4 out of 12 patents)

10. John D Fikes (3 out of 9 patents)

11. Jeffery L Alexander (3 out of 5 patents)

12. Maria A Vitiello (3 out of 4 patents)

13. Robert W Chestnut (2 out of 2 patents)

14. Lilia Maria Babe (1 out of 31 patents)

15. Yiyou Chen (1 out of 12 patents)

17 patents: Sort by Forward Citations

1. 9789181 - PAN-DR binding polypeptides and uses thereof (2017-10-17),

2. 9511134 - Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions (2016-12-06),

3. 9340577 - HLA binding motifs and peptides and their uses (2016-05-17),

4. 9266930 - [object Object] (2016-02-23),

5. 9249187 - Pan-DR binding polypeptides and uses thereof (2016-02-02),

6. 8017745 - [object Object] (2011-09-13),

7. 7888472 - Optimized multi-epitope constructs and uses thereof (2011-02-15),

8. 7026443 - Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions (2006-04-11),

9. 6689363 - Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions (2004-02-10),

10. 6602510 - HLA class I A2 tumor associated antigen peptides and vaccine compositions (2003-08-05),

11. 6534482 - Expression vectors for stimulating an immune response and methods of using the same (2003-03-18),

12. 6464980 - MAGE-1 c-terminal immunogenic peptides (2002-10-15),

13. 6419931 - Compositions and methods for eliciting CTL immunity (2002-07-16),

14. 6413935 - Induction of immune response against desired determinants (2002-07-02),

15. 6413517 - Identification of broadly reactive DR restricted epitopes (2002-07-02),

Company Overview

Epimmune Inc. is a biotechnology company based in San Diego, California, specializing in the development of innovative immunotherapies for the treatment of cancer and infectious diseases. The company focuses on harnessing the power of the immune system to create targeted therapies that enhance the body's natural defenses. With a commitment to advancing medical science, Epimmune is engaged in cutting-edge research and development, aiming to provide effective solutions that address unmet medical needs in the field of immunology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

17 Patents

#341 in San Diego, CA

#4,518 in California

#18,903 in US

#35,948 in the World

San Diego, CA, United States of America

Epimmune Inc.

Forward Citations = 439

30 inventors:

Alessandro D Sette (13 out of 42 patents)

John Sidney (9 out of 17 patents)

Scott Southwood (9 out of 12 patents)

4. Robert W Chesnut (7 out of 15 patents)

5. Esteban Celis (7 out of 19 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Epimmune Inc.. Retrieved from https://idiyas.com/company/epimmune

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…